Bixiye
QP12-20 Reminder for Referring Subscribers to Participating Providers
Taariikhda uu dhaqangalayo Barnaamijka: Jan 22, 2020
Natiijooyinka Raadinta
Soo bandhiga 2121 - 2130 ee natiijooyinka 4233
Bixiye
QP11-20 Pharmacy Benefit Exclusion for Budesonide-Formoterol Fumarate Dihydrate Aerosol
Taariikhda uu dhaqangalayo Barnaamijka: Jan 22, 2020
Bixiye
QP10-20 Pharmacy Benefit Exclusion for Xenleta TM, Asparlas TM, Ogivri TM and Tranexamic Acid/Sodium Chloride
Taariikhda uu dhaqangalayo Barnaamijka: Jan 22, 2020
Bixiye
QP9-20 Pharmacy Benefit Exclusion Healthcare Administered Drugs
Taariikhda uu dhaqangalayo Barnaamijka: Jan 22, 2020
Bixiye
QP15-20 Commercial Medical Drug Exclusion List Expanded to Include Avsola
Taariikhda uu dhaqangalayo Barnaamijka: Jan 22, 2020
Bixiye
QP14-20 New Service Type Options for Inpatient Admission Notifications on Availity Portal
Taariikhda uu dhaqangalayo Barnaamijka: Jan 22, 2020
Bixiye
QP13-20 Blue Cross Blue Shield National Coordination of Care SM Overview
Taariikhda uu dhaqangalayo Barnaamijka: Jan 22, 2020
Bixiye
QP6-20 Separate Remits Will be Sent for Processed Legacy Platform Runout Claims
Taariikhda uu dhaqangalayo Barnaamijka: Jan 08, 2020
Bixiye
QP7-20 Pharmacy Benefit Exclusion for Vyondys 53 (golodirsen)
Taariikhda uu dhaqangalayo Barnaamijka: Jan 08, 2020
Bixiye
QP1-20 Pharmacy Benefit Update – New Drug-Related Prior Authorization (PA) Criteria: Palforzia and Viaskin Peanut (Peanut Allery Oral Immunotherapy)
Taariikhda uu dhaqangalayo Barnaamijka: Jan 08, 2020